María Koehler
About
María Koehler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, María Koehler has authored 112 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in María Koehler's work include HER2/EGFR in Cancer Research (37 papers), Advanced Breast Cancer Therapies (34 papers) and Cancer Treatment and Pharmacology (24 papers). María Koehler is often cited by papers focused on HER2/EGFR in Cancer Research (37 papers), Advanced Breast Cancer Therapies (34 papers) and Cancer Treatment and Pharmacology (24 papers). María Koehler collaborates with scholars based in United States, United Kingdom and Canada. María Koehler's co-authors include Cynthia Huang Bartlett, Nicholas C. Turner, Massimo Cristofanilli, Sherene Loi, Nadia Harbeck, Jungsil Ro, Ke Zhang, Sunil Verma, Hiroji Iwata and Fabrice André and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
María Koehler
109 papers receiving 6.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| María Koehler United States | 26 | 5.0k | 3.4k | 1.9k | 1.5k | 1000 | 112 | 7.0k | ||
| Arlene Chan Australia | 30 | 5.4k 1.1× | 2.3k 0.7× | 1.7k 0.9× | 1.8k 1.2× | 571 0.6× | 144 | 6.8k | ||
| Beth Overmoyer United States | 33 | 4.4k 0.9× | 1.3k 0.4× | 1.9k 1.0× | 1.5k 1.0× | 412 0.4× | 143 | 6.2k | ||
| Erika Hamilton United States | 42 | 6.0k 1.2× | 2.8k 0.8× | 1.3k 0.7× | 1.9k 1.3× | 559 0.6× | 432 | 8.1k | ||
| Eva Ciruelos Spain | 32 | 5.3k 1.1× | 2.3k 0.7× | 2.4k 1.3× | 1.5k 1.0× | 523 0.5× | 208 | 7.1k | ||
| Mark Benyunes United States | 22 | 4.6k 0.9× | 1.5k 0.4× | 1.3k 0.7× | 934 0.6× | 545 0.5× | 37 | 6.1k | ||
| Petri Bono Finland | 44 | 3.9k 0.8× | 2.4k 0.7× | 1.6k 0.8× | 2.7k 1.8× | 293 0.3× | 156 | 7.5k | ||
| Dimosthenis Skarlos Greece | 31 | 4.9k 1.0× | 2.1k 0.6× | 873 0.5× | 1.5k 1.0× | 558 0.6× | 104 | 6.4k | ||
| Roberto Hegg Brazil | 25 | 6.6k 1.3× | 2.3k 0.7× | 2.4k 1.3× | 1.5k 1.0× | 421 0.4× | 87 | 8.3k | ||
| Gwen Fyfe United States | 10 | 5.7k 1.1× | 2.4k 0.7× | 1.6k 0.8× | 3.0k 2.0× | 395 0.4× | 13 | 9.0k | ||
| Alex Bajamonde United States | 7 | 6.8k 1.4× | 1.8k 0.5× | 2.2k 1.1× | 2.9k 1.9× | 509 0.5× | 7 | 9.7k |
Countries citing papers authored by María Koehler
Since
Specialization
Citations
This map shows the geographic impact of María Koehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María Koehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María Koehler more than expected).
Fields of papers citing papers by María Koehler
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by María Koehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María Koehler. The network helps show where María Koehler may publish in the future.
Co-authorship network of co-authors of María Koehler
This figure shows the co-authorship network connecting the top 25 collaborators of María Koehler. A scholar is included among the top collaborators of María Koehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María Koehler. María Koehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ngoi, Natalie Y.L., Ian M. Silverman, Adrienne Johnson, et al.. (2025). Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma. npj Precision Oncology. 9(1). 227–227.
2.
Adjei, Alex A., Kwok‐Kin Wong, María Koehler, et al.. (2024). IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3186–TPS3186.
3.
Fontana, Elisa, Ezra Y. Rosen, Elizabeth K. Lee, et al.. (2024). Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). JNCI Journal of the National Cancer Institute. 116(9). 1439–1449.
4.
Rosen, Ezra Y., Timothy A. Yap, Elizabeth K. Lee, et al.. (2023). Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib. Clinical Cancer Research. 30(4). 687–694.
5.
Mayer, Erica L., Angela DeMichele, Georg Pfeiler, et al.. (2017). PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer. Annals of Oncology. 28. v66–v66.
6.
Cristofanilli, Massimo, Nicholas C. Turner, Igor Bondarenko, et al.. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet Oncology. 17(4). 425–439.
7.
Martín, Miguel, Moshe Inbar, Eva Carrasco, et al.. (2015). Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006). Journal of Clinical Oncology.
8.
Luo, Roger, Jian Ding, Helen Chen, et al.. (2014). Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting. Chinese Journal of Cancer. 33(12). 620–4.
9.
Blackwell, Kimberly, Harold J. Burstein, Anna Maria Storniolo, et al.. (2010). Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology. 28(7). 1124–1130.
10.
Scaltriti, Maurizio, Sarat Chandarlapaty, Ludmila Prudkin, et al.. (2010). Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research. 16(9). 2688–2695.
11.
Finn, Richard S., Michael F. Press, Judy Dering, et al.. (2009). Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer. Journal of Clinical Oncology. 27(24). 3908–3915.
12.
Leo, Angelo Di, Henry Gómez, Zeba Aziz, et al.. (2008). Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. Journal of Clinical Oncology. 26(34). 5544–5552.
13.
Press, Michael F., Richard S. Finn, David Cameron, et al.. (2008). HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research. 14(23). 7861–7870.
14.
Schanz, Julie, Claudia Wolf, María Koehler, et al.. (2004). Rhabdomyolysis in allogeneic peripheral blood stem cell donors. Vox Sanguinis. 86(4). 263–265.
15.
Hord, Jeffrey D., et al.. (2002). Diminished Antibody Response to Hepatitis B Immunization in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology. 24(7). 548–549.
16.
Neudorf, Steven, Witold B. Rybka, Edward D. Ball, et al.. (1997). The Use of Counterflow Centrifugal Elutriation for the Depletion of T Cells from Unrelated Donor Bone Marrow. Journal of Hematotherapy. 6(4). 351–359.
17.
Henwick, Scott, María Koehler, & C C Patrick. (1993). Complications of Bacteremia Due to Stomatococcus mucilaginosus in Neutropenic Children. Clinical Infectious Diseases. 17(4). 667–671.
18.
Hołowiecki, Jerzy, María Koehler, G Kardos, et al.. (1992). Childhood Acute Lymphoblastic Leukemia Immunophenotypes and their Prognostic Significance: Experience of the IGCI-Study in 389 Children. Leukemia & lymphoma. 7(3). 225–234.
19.
Koehler, María, et al.. (1988). The effects of long term methotrexate therapy on the gonadal function and morphology.. PubMed. 39(1). 33–40.
20.
Koehler, María, U. Heinrich, R. Ludwig, Rüdiger Waldherr, & W. Brandeis. (1986). Effects of Methotrexate on Rabbit Testes Part 2: Hormonal Changes. Pediatric Hematology and Oncology. 3(4). 335–341.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Arlene Chan Breakdown of academic impact, for papers by Beth Overmoyer Breakdown of academic impact, for papers by Erika Hamilton Breakdown of academic impact, for papers by Eva Ciruelos Breakdown of academic impact, for papers by Mark Benyunes Breakdown of academic impact, for papers by Petri Bono Breakdown of academic impact, for papers by Dimosthenis Skarlos Breakdown of academic impact, for papers by Roberto Hegg Breakdown of academic impact, for papers by Gwen Fyfe Breakdown of academic impact, for papers by Alex Bajamonde